Novo Nordisk has just released the results of the phase 3 STEP-HFpEF trial showing that semaglutide was able to reduce symptoms and improve exercise capacity in overweight people with heart failure.

Positive data could also support label expansions for existing products, such as the potential use of Wegovy in heart failure patients based on the STEP-HFpEF trial results. These expanded ...

Positive data could also support label expansions for existing products, such as the potential use of Wegovy in heart failure patients based on the STEP-HFpEF trial results. These expanded indications ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

The positive opinion is based on results from the STEP HFpEF and the STEP HFpEF-DM trials. Further a positive opinion was also issued based on data from the STEP 9 trial in people with obesity and ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Medscape Medical News, October 10, 2023 HFSA 2023 Semaglutide Win in HFpEF With Obesity Regardless of LVEF Were the GLP-1 receptor agonist drug's apparent benefits in STEP-HFpEF due solely to ...

A key difference between SUMMIT and Novo Nordisk's STEP-HFpEF study of semaglutide is that it included hard cardiovascular outcomes as the primary endpoint. In contrast, Novo Nordisk's study ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv ...